.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,403,649

« Back to Dashboard

Summary for Patent: 6,403,649

Title: Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents
Abstract:The present invention provides cydopentane heptanoic acid, 2-cycloalkyl or arylalkyl compounds, which may be substituted in the 1-position with amino, amido, ether or ester groups, e.g., a 1-OH cydopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compound. The cydopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compounds of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma. Moreover, the cydopentane heptanoic, 2-(cycloalkyl or arylalkyl) compounds of this invention are smooth muscle relaxants with broad application in systemic hypertensive and pulmonary diseases; smooth muscle relaxants with application in gastrointestinal disease, reproduction, fertility, incontinence, shock, etc.
Inventor(s): Woodward; David F. (El Toro, CA), Andrews; Steven W. (Rancho Santa Marguerita, CA), Burk; Robert M. (Irvine, CA), Garst; Michael E. (Newport Beach, CA)
Assignee: Allergan Sales, Inc. (Irvine, CA)
Application Number:09/519,834
Patent Claim Types:
see list of patent claims
Compound; Use;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 28th percentile
Forward Citations: 1st percentile
Patent PDF download available with subscription

No matches for this query

Premature patent expiration for: 6,403,649

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
6,403,649 June 11, 2014

International Patent Family for Patent: 6,403,649

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Spain2159734<disabled in preview>
Japan3681068<disabled in preview>
JapanH08501310<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

`abc